Suggestions
Amit Etkin
Founder and CEO at Alto Neuroscience | Professor (Psychiatry) at Stanford University
Amit Etkin, MD, PhD, is a prominent figure in the field of psychiatry and neuroscience. He is currently the Founder and CEO of Alto Neuroscience, a clinical-stage company, while also serving as an Adjunct Professor of Psychiatry and Behavioral Sciences at Stanford University.135
Dr. Etkin's career highlights include:
-
Education: He received his MD/PhD from Columbia University, studying under Nobel laureate Eric Kandel. He completed his psychiatry residency and postdoctoral fellowship at Stanford University.14
-
Academic career: Dr. Etkin joined Stanford's faculty in 2010, progressing from Assistant Professor to tenured Professor. He is known for his research on the neuroscience of psychiatric disorders and their treatments.45
-
Research recognition: He received the prestigious NIH Director's Pioneer Award, the first given in clinical psychiatry. Dr. Etkin consistently ranks in the top 0.1% of researchers by citations.4
-
Current roles: In addition to his position at Alto Neuroscience, which he founded in 2019, Dr. Etkin maintains his affiliation with Stanford University as an Adjunct Professor.56
-
Research focus: His work aims to understand the neural basis of emotional disorders and their treatment, with the goal of developing novel interventions.1
Dr. Etkin is recognized for his interdisciplinary approach, combining his expertise as both a neuroscientist and psychiatrist to advance the field of precision psychiatry.24
Highlights
Excited to see our review at Neuropsychopharmacology published today, co-written with two of our leaders at Alto Neuroscience, Adam Savitz and Jessica Powell!
We provide a perspective for how different types of neuroimaging (EEG, MRI, PET) can be used at various stages of drug development to de-risk what is currently a low-odds trial-and-error process not directly guided by human neurobiology.
"Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective"
read it here (open access): https://rdcu.be/dRAQm
Really looking forward to this fireside chat at the AI x Bio summit, hosted at the NYSE with Decoding Bio in NYC next week, moderated by Eric J. Dimise, PhD. See you there!
